drugset / Trial / NCT01251536
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Phase 2
Completed
108 enrolled
Universitaire Ziekenhuizen KU Leuven
Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study the molecular signatures of response.
Timeline
- Start
- 2010-12
- Primary completion
- 2016-06
- Completion
- 2019-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | — |